How New Treatments are Fueling the Boom in Biotech Stocks

The big pharmaceutical companies get much of the credit for the swell of revolutionary innovations and treatments in the healthcare sector. But those innovations aren’t limited to the big boys.

Biotech stocks have been red-hot this year, and a major reason for it is the glut of promising treatments being developed for diseases that have long been woefully undertreated. Many of the companies discovering and testing those groundbreaking treatments are small, clinical-stage biotechs with no revenues and very little coverage on Wall Street. At least until recently. 

Lately, investors have been piling in to biotech stocks in droves. Nearly every exchange-traded fund (ETF) that tracks the biotech sector is up more than 20% year-to-date. Here are a few examples: 

Biotech Stocks
  • iShares Nasdaq Biotechnology (IBB): +21%
  • BioShares Biotechnology Clinical Trials (BBC): +30%
  • SPDR S&P Biotech ETF (XBI): +30.6%
  • ProShares Ultra Nasdaq Biotechnology (BIB): +43.4%

Not bad, when you consider that the S&P 500 is up just 2.5% in 2015. Biotech stocks are known for high rewards, but those rewards typically come during times when the broad market is flourishing. Right now, biotechs are prospering at a time when most stocks are stuck in the mud.

It seems the rise of new treatments is one of the few things that has investors licking their chops these days. And with good reason. Groundbreaking treatments are sprouting up everywhere, and many of them are on the brink of being approved for commercial use. Savvy growth investors—particularly small-cap investors—know that the best time to invest in biotech stocks is before their products or technologies become mainstream. Biotechs that are showing promising results in early clinical trials but remain in the later clinical stages make for ideal investments.

Though not a small cap, Biogen (BIIB) is one example, recently gaining approval for a new Alzheimer’s drug. A number of smaller companies are developing cancer treatments, and many of them have gained the coveted “Breakthrough Therapy” designation from the Food and Drug Administration. Heart failure, diabetes, HIV and glaucoma are among the other diseases with new treatments entering or close to entering the marketplace thanks to advances in modern medicine.

It’s all very exciting, with potential worldwide client bases measuring in the hundreds of millions. The sheer numbers have captivated Wall Street, and the steady stream of media coverage of those new treatments has held investors’ attention. The question is: How long will it last? How much longer can biotech stocks thrive, especially while the rest of the market plods along aimlessly?

Ultimately, it will depend on which way the market goes once investors finally make up their minds. Biotech stocks can thrive in a bull market and even a sideways one; they simply cannot survive in a down market.

A breakout one way or another is coming. If stocks start to decline, you’ll surely want to get out of biotechs immediately—regardless of how many of these in-development drugs get approved. But, if the market breaks to the upside, as it has been doing repeatedly for four straight years now (the S&P hasn’t had a correction of 10% or more since July 2011), expect biotech stocks to get a second wind.

New, revolutionary treatments have surely played a major role in this year’s rush to biotechs. In fact, our Cabot Small-Cap Confidential advisory has almost exclusively recommended biotech stocks of late, and chief analyst Tom Garrity thinks several of them have a chance to double or triple in value if their products get approved for commercial distribution.

To learn more about Tom’s biotech recommendations, click here.

Headline News

Stock Picks


Shopify (SHOP), which came public in May of last year, is a new leader.


Roy Ward uses the PEG ratio to determine if the stock is undervalued or overvalued.

For AMZN to be undervalued, the stock would need to fall to 393. 50.

Cabot Wealth Advisory

The Emerging Market Stock You Ought to Own

By Paul Goodwin on September 27, 2016

The company I’m talking about (the one that you probably don’t own) is the largest Chinese instant messaging company. It is a giant in its own right, with a market cap of $262 billion and annual sales of over $19 billion. The company grew revenue by 28% in 2015 and routinely boasts after-tax profit margins over 30%.Read More >

Tesla Model 3 vs. Chevy Bolt: Which Affordable Electric Car Is Better?

By Timothy Lutts on September 26, 2016

The Tesla Model 3 and Chevy Bolt are the first two affordable electric cars with a driving range of more than 200 miles. Let’s see how they stack up - and what they could mean to Tesla Motors (TSLA) and General Motors (GM) stock. Read More >

Does Alibaba (BABA) Stock Measure Up to Amazon (AMZN)?

By Paul Goodwin on September 23, 2016

Alibaba (BABA) is the Amazon (AMZN) of China. But does BABA stock measure up to AMZN stock? Let’s break it down!Read More >